Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-19
1996-02-13
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514262, 514263, 544244, 544263, 544264, 544265, 544277, A61K 3152, C07D47318, C07D47332, C07D47334
Patent
active
054911460
ABSTRACT:
This invention discloses various analogs of erythro-hydroxynonyladenine (EHNA) which have been modified by the addition of hydroxy groups or other moieties at the #8 or #9 carbon atoms of the side-chain portion of the molecule (i.e., the erythro-hydroxynonyl chain which is attached to the adenosine ring structure). It also discloses synthetic reagents and steps that can be used to create these and other analogs of EHNA which contain hydroxyl, halide, acid, ester, ether, amine, azide, or other moieties at such locations, or at other controllable locations such as the #5, #6, or #7 carbon atoms on the side-chain. Analogs containing such side-chain modifications can also be modified in the adenosine structure if desired. The hydroxylated analogs described herein have been shown to inhibit adenosine deaminase (ADA) at therapeutically useful levels. The relevant Ki values are in the range of 10.sup.-8 to 10.sup.-9, which is within a desired range of about 10.sup.-7 to about 10.sup.-10. EHNA analogs that have potencies within this range can effectively inhibit ADA activity on a reversible basis, without permanently poisoning the enzyme. It has also been discovered that some of these analogs have an additional therapeutic value when used to protect heart muscle against ischemic damage.
REFERENCES:
patent: 5284837 (1994-02-01), Lindborg et al.
Abushanab, E., et al, "Practical Enantiospecific Synthesis of (+)-erythro-9-(2-Hydroxy-3-nonyl)adenine," Tetrahedron Lett. 25: 3841 (1984).
Harriman, G. C. B., et al, "Adenosine Deaminase Inhibitors: Synthesis and Biological Evaluation of C1' and Nor-C1' Derivatives of (+)-erythro-9-(2(S)-Hydroxy-3(R)-nonyl)adenine," J. Med. Chem. 35: 4180-4184 (1992).
Bastian, G., et al, "Adenosine Deaminase Inhibitors: Conversion of a Single Chiral Synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines," J. Med. Chem. 24:1383-1385 (1981).
Baker, D. C., and Hawkins, L. D., "Synthesis of Inhibitors of Adenosine Deaminase: A Total Synthesis of erythro-3-(Adenin-9-yl)-2-nonanol and Its Isomers from Chiral Precursors," J. Org. Chem. 47: 2179-2184 (1982).
Cristalli, G., et al, "Adenosine Deaminase Inhibitors: Synthesis and Biological Activity of Deaza Analogues of erythro-9-(2-Hydroxy-3-nonyl)adenine," J. Med. Chem. 31: 390-397 (1988).
Cristalli, G., et al, "Adenosine Deaminase Inhibitors: Synthesis and Structure-Activity Relationships of Imidazole Analogues of erythro-9-(2-Hydroxy-3-nonyl)adenine," J. Med. Chem. 34: 1187-1192 (1991).
Abushanab, E., "L-ascorbic and D-isoascorbic acids: chiron sources for 1',2'-seco-nucleosides/tides, phosphonates, and other molecules of biological interest," pp. 159-175 in Nucleosides and Nucleotides as Antitumor and Antiviral Agents, C. K. Chu and D. C. Baker, eds. (Plenum Press, New York, 1993).
Abushanab et al I, Tetrahedron Letters, vol. 25, No. 35, pp. 3841-3844 (1984).
Abushanab et al II, J. Org. Chem., vol. 53, pp. 2598-2602 (1988).
Antonini et al, J. Med. Chem., vol. 27, pp. 274-278 (1984).
Baker et al, J. Org. Chem., vol. 47, pp. 2179-2184 (1982).
Bastian et al, J. Med. Chem., vol. 24, pp. 1383-1385 (1981).
Cristalli et al, J. Med. Chem., vol. 31, pp. 390-393 (1988).
Harriman et al, J. Med. Chem., vol. 35, pp. 4180-4184 (1992).
Porter et al, Biochemistry, vol. 31, No. 35, pp. 8216-8220 (1992).
Cypros Pharmaceutical Corporation
Higel Floyd D.
Kelly Patrick D.
LandOfFree
Hydroxylated erythro-hydroxynonyladenines and related analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxylated erythro-hydroxynonyladenines and related analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxylated erythro-hydroxynonyladenines and related analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-240747